Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation

Ayumi Fujimoto, Nobuhiro Hiramoto, Satoshi Yamasaki, Yoshihiro Inamoto, Naoyuki Uchida, Tetsuo Maeda, Takehiko Mori, Yoshinobu Kanda, Tadakazu Kondo, Souichi Shiratori, Shigesaburo Miyakoshi, Ken Ishiyama, Kazuhiro Ikegame, Yoshiko Matsuhashi, Junji Tanaka, Tatsuo Ichinohe, Yoshiko Atsuta, Masao Ogata, Ritsuro Suzuki

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We analyzed data from 64,539 consecutive patients in the Japanese national transplant registry, including 40,195 after allogeneic hematopoietic stem cell transplantation (HSCT), 24,215 after autologous HSCT and 129 after syngeneic HSCT, of whom 299 developed Epstein-Barr virus-positive post-transplant lymphoproliferative disorder (PTLD). The probability of developing PTLD at 2years post-HSCT was.79% after allogeneic transplantation,.78% after syngeneic transplantation, and.11% after autologous transplantation. The following variables were identified as risk factors after allogeneic HSCT in multivariate analysis: antithymocyte globulin (ATG) use in a conditioning regimen, ATG use for acute graft-versus-host disease (GVHD) treatment, donor other than an HLA-matched related donor, aplastic anemia, second or subsequent allogeneic HSCT, the most recent year of transplantation, and acute GVHD. The probability at 2years increased particularly after 2009 (1.24%) than before 2009 (.45%). To stratify the risk of PTLD before allogeneic HSCT, we developed a novel 5-point scoring system based on 3 pretransplant risk factors: ATG use in a conditioning regimen (high dose, 2 points; low dose, 1 point), donor type (HLA-mismatched related donor, 1 point; unrelated donor, 1 point; cord blood, 2 points), and aplastic anemia (1 point). Patients were classified into 4 risk groups according to the summed points: low risk (0 or 1 point), intermediate risk (2 points), high risk (3 points), and very high risk (4 or 5 points) groups, with probabilities at 2years of.3%, 1.3%, 4.6%, and 11.5%, respectively. Our scoring system is useful for predicting patients at high risk for PTLD. Careful observation and close monitoring of Epstein-Barr virus reactivation are warranted for these high-risk patients.

Original languageEnglish
JournalBiology of Blood and Marrow Transplantation
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Lymphoproliferative Disorders
Hematopoietic Stem Cell Transplantation
Transplants
Antilymphocyte Serum
Tissue Donors
Aplastic Anemia
Graft vs Host Disease
Human Herpesvirus 4
Isogeneic Transplantation
Unrelated Donors
Autologous Transplantation
Homologous Transplantation
Fetal Blood
Registries
Multivariate Analysis
Transplantation
Observation

Keywords

  • Hematopoietic stem cell transplantation
  • Post-transplant lymphoproliferative disorder
  • Predictive scoring system

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation. / Fujimoto, Ayumi; Hiramoto, Nobuhiro; Yamasaki, Satoshi; Inamoto, Yoshihiro; Uchida, Naoyuki; Maeda, Tetsuo; Mori, Takehiko; Kanda, Yoshinobu; Kondo, Tadakazu; Shiratori, Souichi; Miyakoshi, Shigesaburo; Ishiyama, Ken; Ikegame, Kazuhiro; Matsuhashi, Yoshiko; Tanaka, Junji; Ichinohe, Tatsuo; Atsuta, Yoshiko; Ogata, Masao; Suzuki, Ritsuro.

In: Biology of Blood and Marrow Transplantation, 01.01.2019.

Research output: Contribution to journalArticle

Fujimoto, A, Hiramoto, N, Yamasaki, S, Inamoto, Y, Uchida, N, Maeda, T, Mori, T, Kanda, Y, Kondo, T, Shiratori, S, Miyakoshi, S, Ishiyama, K, Ikegame, K, Matsuhashi, Y, Tanaka, J, Ichinohe, T, Atsuta, Y, Ogata, M & Suzuki, R 2019, 'Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation', Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2019.02.016
Fujimoto, Ayumi ; Hiramoto, Nobuhiro ; Yamasaki, Satoshi ; Inamoto, Yoshihiro ; Uchida, Naoyuki ; Maeda, Tetsuo ; Mori, Takehiko ; Kanda, Yoshinobu ; Kondo, Tadakazu ; Shiratori, Souichi ; Miyakoshi, Shigesaburo ; Ishiyama, Ken ; Ikegame, Kazuhiro ; Matsuhashi, Yoshiko ; Tanaka, Junji ; Ichinohe, Tatsuo ; Atsuta, Yoshiko ; Ogata, Masao ; Suzuki, Ritsuro. / Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation. In: Biology of Blood and Marrow Transplantation. 2019.
@article{c14233fc9af746db897504b1ead93218,
title = "Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation",
abstract = "We analyzed data from 64,539 consecutive patients in the Japanese national transplant registry, including 40,195 after allogeneic hematopoietic stem cell transplantation (HSCT), 24,215 after autologous HSCT and 129 after syngeneic HSCT, of whom 299 developed Epstein-Barr virus-positive post-transplant lymphoproliferative disorder (PTLD). The probability of developing PTLD at 2years post-HSCT was.79{\%} after allogeneic transplantation,.78{\%} after syngeneic transplantation, and.11{\%} after autologous transplantation. The following variables were identified as risk factors after allogeneic HSCT in multivariate analysis: antithymocyte globulin (ATG) use in a conditioning regimen, ATG use for acute graft-versus-host disease (GVHD) treatment, donor other than an HLA-matched related donor, aplastic anemia, second or subsequent allogeneic HSCT, the most recent year of transplantation, and acute GVHD. The probability at 2years increased particularly after 2009 (1.24{\%}) than before 2009 (.45{\%}). To stratify the risk of PTLD before allogeneic HSCT, we developed a novel 5-point scoring system based on 3 pretransplant risk factors: ATG use in a conditioning regimen (high dose, 2 points; low dose, 1 point), donor type (HLA-mismatched related donor, 1 point; unrelated donor, 1 point; cord blood, 2 points), and aplastic anemia (1 point). Patients were classified into 4 risk groups according to the summed points: low risk (0 or 1 point), intermediate risk (2 points), high risk (3 points), and very high risk (4 or 5 points) groups, with probabilities at 2years of.3{\%}, 1.3{\%}, 4.6{\%}, and 11.5{\%}, respectively. Our scoring system is useful for predicting patients at high risk for PTLD. Careful observation and close monitoring of Epstein-Barr virus reactivation are warranted for these high-risk patients.",
keywords = "Hematopoietic stem cell transplantation, Post-transplant lymphoproliferative disorder, Predictive scoring system",
author = "Ayumi Fujimoto and Nobuhiro Hiramoto and Satoshi Yamasaki and Yoshihiro Inamoto and Naoyuki Uchida and Tetsuo Maeda and Takehiko Mori and Yoshinobu Kanda and Tadakazu Kondo and Souichi Shiratori and Shigesaburo Miyakoshi and Ken Ishiyama and Kazuhiro Ikegame and Yoshiko Matsuhashi and Junji Tanaka and Tatsuo Ichinohe and Yoshiko Atsuta and Masao Ogata and Ritsuro Suzuki",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.bbmt.2019.02.016",
language = "English",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation

AU - Fujimoto, Ayumi

AU - Hiramoto, Nobuhiro

AU - Yamasaki, Satoshi

AU - Inamoto, Yoshihiro

AU - Uchida, Naoyuki

AU - Maeda, Tetsuo

AU - Mori, Takehiko

AU - Kanda, Yoshinobu

AU - Kondo, Tadakazu

AU - Shiratori, Souichi

AU - Miyakoshi, Shigesaburo

AU - Ishiyama, Ken

AU - Ikegame, Kazuhiro

AU - Matsuhashi, Yoshiko

AU - Tanaka, Junji

AU - Ichinohe, Tatsuo

AU - Atsuta, Yoshiko

AU - Ogata, Masao

AU - Suzuki, Ritsuro

PY - 2019/1/1

Y1 - 2019/1/1

N2 - We analyzed data from 64,539 consecutive patients in the Japanese national transplant registry, including 40,195 after allogeneic hematopoietic stem cell transplantation (HSCT), 24,215 after autologous HSCT and 129 after syngeneic HSCT, of whom 299 developed Epstein-Barr virus-positive post-transplant lymphoproliferative disorder (PTLD). The probability of developing PTLD at 2years post-HSCT was.79% after allogeneic transplantation,.78% after syngeneic transplantation, and.11% after autologous transplantation. The following variables were identified as risk factors after allogeneic HSCT in multivariate analysis: antithymocyte globulin (ATG) use in a conditioning regimen, ATG use for acute graft-versus-host disease (GVHD) treatment, donor other than an HLA-matched related donor, aplastic anemia, second or subsequent allogeneic HSCT, the most recent year of transplantation, and acute GVHD. The probability at 2years increased particularly after 2009 (1.24%) than before 2009 (.45%). To stratify the risk of PTLD before allogeneic HSCT, we developed a novel 5-point scoring system based on 3 pretransplant risk factors: ATG use in a conditioning regimen (high dose, 2 points; low dose, 1 point), donor type (HLA-mismatched related donor, 1 point; unrelated donor, 1 point; cord blood, 2 points), and aplastic anemia (1 point). Patients were classified into 4 risk groups according to the summed points: low risk (0 or 1 point), intermediate risk (2 points), high risk (3 points), and very high risk (4 or 5 points) groups, with probabilities at 2years of.3%, 1.3%, 4.6%, and 11.5%, respectively. Our scoring system is useful for predicting patients at high risk for PTLD. Careful observation and close monitoring of Epstein-Barr virus reactivation are warranted for these high-risk patients.

AB - We analyzed data from 64,539 consecutive patients in the Japanese national transplant registry, including 40,195 after allogeneic hematopoietic stem cell transplantation (HSCT), 24,215 after autologous HSCT and 129 after syngeneic HSCT, of whom 299 developed Epstein-Barr virus-positive post-transplant lymphoproliferative disorder (PTLD). The probability of developing PTLD at 2years post-HSCT was.79% after allogeneic transplantation,.78% after syngeneic transplantation, and.11% after autologous transplantation. The following variables were identified as risk factors after allogeneic HSCT in multivariate analysis: antithymocyte globulin (ATG) use in a conditioning regimen, ATG use for acute graft-versus-host disease (GVHD) treatment, donor other than an HLA-matched related donor, aplastic anemia, second or subsequent allogeneic HSCT, the most recent year of transplantation, and acute GVHD. The probability at 2years increased particularly after 2009 (1.24%) than before 2009 (.45%). To stratify the risk of PTLD before allogeneic HSCT, we developed a novel 5-point scoring system based on 3 pretransplant risk factors: ATG use in a conditioning regimen (high dose, 2 points; low dose, 1 point), donor type (HLA-mismatched related donor, 1 point; unrelated donor, 1 point; cord blood, 2 points), and aplastic anemia (1 point). Patients were classified into 4 risk groups according to the summed points: low risk (0 or 1 point), intermediate risk (2 points), high risk (3 points), and very high risk (4 or 5 points) groups, with probabilities at 2years of.3%, 1.3%, 4.6%, and 11.5%, respectively. Our scoring system is useful for predicting patients at high risk for PTLD. Careful observation and close monitoring of Epstein-Barr virus reactivation are warranted for these high-risk patients.

KW - Hematopoietic stem cell transplantation

KW - Post-transplant lymphoproliferative disorder

KW - Predictive scoring system

UR - http://www.scopus.com/inward/record.url?scp=85063443813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063443813&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2019.02.016

DO - 10.1016/j.bbmt.2019.02.016

M3 - Article

C2 - 30794929

AN - SCOPUS:85063443813

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

ER -